Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de neuro-psiquiatria (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200007 |
Resumo: | Mitoxantrone hydrochloride (Novantrone®) is an anthracenedione that has been used as one of the latest in a long line of general immunosuppresive agents studied in multiple sclerosis (MS). We reviewed the clinical, laboratory, neuroimaging and echocardiography data of 18 patients from February 2001 to March 2004 out of a total number of 100 patients with definite MS. Fourteen patients were women (77.7%) and four were men. The mean age of the patients was 41.6±10 years old (confidence intervals 95%: 36.4-46.7 years old). The mean duration of disease was 10.5±6.3 years. Fourteen patients had the secondarily progressive form of MS, and four had the relapsing-remitting form. Mitoxantrone is an useful and clinically effective drug in MS and its major limitation is the potencial cardiotoxicity due to cumulative dose (140 mg). |
id |
ABNEURO-1_2237d814d7e28458cf15376d71cbd7a8 |
---|---|
oai_identifier_str |
oai:scielo:S0004-282X2005000200007 |
network_acronym_str |
ABNEURO-1 |
network_name_str |
Arquivos de neuro-psiquiatria (Online) |
repository_id_str |
|
spelling |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patientsmitoxantronemultiple sclerosisdemyelinating diseaseMitoxantrone hydrochloride (Novantrone®) is an anthracenedione that has been used as one of the latest in a long line of general immunosuppresive agents studied in multiple sclerosis (MS). We reviewed the clinical, laboratory, neuroimaging and echocardiography data of 18 patients from February 2001 to March 2004 out of a total number of 100 patients with definite MS. Fourteen patients were women (77.7%) and four were men. The mean age of the patients was 41.6±10 years old (confidence intervals 95%: 36.4-46.7 years old). The mean duration of disease was 10.5±6.3 years. Fourteen patients had the secondarily progressive form of MS, and four had the relapsing-remitting form. Mitoxantrone is an useful and clinically effective drug in MS and its major limitation is the potencial cardiotoxicity due to cumulative dose (140 mg).Academia Brasileira de Neurologia - ABNEURO2005-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200007Arquivos de Neuro-Psiquiatria v.63 n.2a 2005reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/S0004-282X2005000200007info:eu-repo/semantics/openAccessMontú,María BelénArruda,Walter OleschkoOliveira,Marcelo de Souza R. deRamina,Ricardoeng2005-07-05T00:00:00Zoai:scielo:S0004-282X2005000200007Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2005-07-05T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse |
dc.title.none.fl_str_mv |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients |
title |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients |
spellingShingle |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients Montú,María Belén mitoxantrone multiple sclerosis demyelinating disease |
title_short |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients |
title_full |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients |
title_fullStr |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients |
title_full_unstemmed |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients |
title_sort |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients |
author |
Montú,María Belén |
author_facet |
Montú,María Belén Arruda,Walter Oleschko Oliveira,Marcelo de Souza R. de Ramina,Ricardo |
author_role |
author |
author2 |
Arruda,Walter Oleschko Oliveira,Marcelo de Souza R. de Ramina,Ricardo |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Montú,María Belén Arruda,Walter Oleschko Oliveira,Marcelo de Souza R. de Ramina,Ricardo |
dc.subject.por.fl_str_mv |
mitoxantrone multiple sclerosis demyelinating disease |
topic |
mitoxantrone multiple sclerosis demyelinating disease |
description |
Mitoxantrone hydrochloride (Novantrone®) is an anthracenedione that has been used as one of the latest in a long line of general immunosuppresive agents studied in multiple sclerosis (MS). We reviewed the clinical, laboratory, neuroimaging and echocardiography data of 18 patients from February 2001 to March 2004 out of a total number of 100 patients with definite MS. Fourteen patients were women (77.7%) and four were men. The mean age of the patients was 41.6±10 years old (confidence intervals 95%: 36.4-46.7 years old). The mean duration of disease was 10.5±6.3 years. Fourteen patients had the secondarily progressive form of MS, and four had the relapsing-remitting form. Mitoxantrone is an useful and clinically effective drug in MS and its major limitation is the potencial cardiotoxicity due to cumulative dose (140 mg). |
publishDate |
2005 |
dc.date.none.fl_str_mv |
2005-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200007 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200007 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0004-282X2005000200007 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
dc.source.none.fl_str_mv |
Arquivos de Neuro-Psiquiatria v.63 n.2a 2005 reponame:Arquivos de neuro-psiquiatria (Online) instname:Academia Brasileira de Neurologia instacron:ABNEURO |
instname_str |
Academia Brasileira de Neurologia |
instacron_str |
ABNEURO |
institution |
ABNEURO |
reponame_str |
Arquivos de neuro-psiquiatria (Online) |
collection |
Arquivos de neuro-psiquiatria (Online) |
repository.name.fl_str_mv |
Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia |
repository.mail.fl_str_mv |
||revista.arquivos@abneuro.org |
_version_ |
1754212757943615488 |